Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 3, 2006

Biogen Idec Inks Deal with UCB Worth over $200M

  • UCB and Biogen Idec are partnering to develop and commercialize CDP323 for the treatment of relapsing-remitting multiple sclerosis (MS) and other potential indications. CDP323 is an orally active small molecule alpha4-integrin inhibitor expected to enter Phase II trials next year.

    Under terms of the agreement, UCB will receive upfront and additional payments for development and commercial milestones in excess of $200 million. Furthermore Biogen Idec will contribute significantly to clinical costs for Phase II and Phase III studies. All commercialization costs and profits will be shared equally.

    “We are always looking to enhance and expand our arsenal in the fight against MS,” said Al Sandrock, senior vp, neurology research and development for Biogen Idec. “Another effective oral therapy would augment Biogen Idec’s broad portfolio of products and potential therapies in development for this debilitating disease.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »